-
EP3796903
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3796903
| EP3796903 - CANNABINOIDS AND/OR TERPENES FOR USE IN TRPV1 MODULATION [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 01.12.2023 Database last updated on 17.08.2024 | |
| Former | Examination is in progress Status updated on 24.03.2023 | ||
| Former | Request for examination was made Status updated on 26.02.2021 | ||
| Former | The international publication has been made Status updated on 30.11.2019 | ||
| Former | unknown Status updated on 25.06.2019 | Most recent event Tooltip | 01.12.2023 | Application deemed to be withdrawn | published on 03.01.2024 [2024/01] | Applicant(s) | For all designated states GBS Global Biopharma, Inc. 900 Morrison Drive Suite 200 Ottawa, Ontario K2H 8K7 / CA | [2021/13] | Inventor(s) | 01 /
SMALL-HOWARD, Andrea c/o GBS Global BioPharma, Inc. 900 Morrison Drive Suite 200 Ottawa, Ontario K2H 8K7 / CA | 02 /
TURNER, Helen c/o GBS Global BioPharma, Inc. 900 Morrison Drive Suite 200 Ottawa, Ontario K2H 8K7 Canada / CA | [2021/13] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [N/P] |
| Former [2021/13] | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | Application number, filing date | 19731026.1 | 22.05.2019 | [2021/13] | WO2019US33618 | Priority number, date | US201862674843P | 22.05.2018 Original published format: US 201862674843 P | US201862769743P | 20.11.2018 Original published format: US 201862769743 P | US201962849719P | 17.05.2019 Original published format: US 201962849719 P | [2021/13] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019226833 | Date: | 28.11.2019 | Language: | EN | [2019/48] | Type: | A1 Application with search report | No.: | EP3796903 | Date: | 31.03.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.11.2019 takes the place of the publication of the European patent application. | [2021/13] | Search report(s) | International search report - published on: | EP | 28.11.2019 | Classification | IPC: | A61K31/352, A61K31/015, A61K31/045, A61P29/00, A61P9/00 | [2021/13] | CPC: |
A61K31/352 (EP,IL,US);
A61K31/01 (IL,US);
A61K31/015 (EP,IL);
A61K31/045 (EP,IL);
A61K31/05 (IL,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/13] | Title | German: | CANNABINOIDE UND/ODER TERPENE ZUR VERWENDUNG IN DER TRPV1-MODULATION | [2021/13] | English: | CANNABINOIDS AND/OR TERPENES FOR USE IN TRPV1 MODULATION | [2021/13] | French: | CANNABINOÏDES ET/OU TERPÈNES DESTINÉS À ÊTRE UTILISÉS DANS LA MODULATION TRPV1 | [2021/13] | Entry into regional phase | 02.12.2020 | National basic fee paid | 02.12.2020 | Designation fee(s) paid | 02.12.2020 | Examination fee paid | Examination procedure | 02.12.2020 | Examination requested [2021/13] | 02.12.2020 | Date on which the examining division has become responsible | 22.07.2021 | Amendment by applicant (claims and/or description) | 30.03.2023 | Despatch of a communication from the examining division (Time limit: M04) | 10.08.2023 | Application deemed to be withdrawn, date of legal effect [2024/01] | 31.08.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2024/01] | Fees paid | Renewal fee | 27.05.2021 | Renewal fee patent year 03 | 27.05.2022 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 31.05.2023 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2007047752 (ALLERGAN INC [US], et al) [X] 1-10,23-27,29,52-56 * page 2, paragraph 1 *; | [XP]WO2018217803 (GROWBLOX LIFE SCIENCES L L C [US]) [XP] 1-57 * claims 1,61,74 *; | [T] - PLANELLS-CASES ROSA ET AL, "Small molecules targeting the vanilloid receptor complex as drugs for inflammatory pain.", DRUGS OF THE FUTURE, (200308), vol. 28, no. 8, ISSN 0377-8282, pages 787 - 795, XP002793801 [T] * the whole document * DOI: http://dx.doi.org/10.1358/dof.2003.028.08.747395 | [X] - CUNETTI L ET AL, "Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay", TRANSPLANTATION PROCEEDINGS, (201803), vol. 50, no. 2, ISSN 0041-1345, pages 461 - 464, XP009510726 [X] 1-11,13,23-27,29,52-56 * page 461, abstract * DOI: http://dx.doi.org/10.1016/j.transproceed.2017.12.042 pubmed:29579828 | [X] - GOMES PAULA-FREIRE LYVIA IZAURA ET AL, "Ocimum gratissimum Essential Oil and Its Isolated Compounds (Eugenol and Myrcene) Reduce Neuropathic Pain in Mice", PLANTA MEDICA, (201602), vol. 82, no. 3, pages 211 - 216, XP002793802 [X] 1-11,17,23-27,29,52-56 * page 211, abstract * | [X] - KATSUYAMA SOH ET AL, "Intraplantar injection of linalool reduces paclitaxel-induced acute pain in mice", BIOMEDICAL RESEARCH (TOKYO), (201206), vol. 33, no. 3, pages 175 - 181, XP002793803 [X] 1-11,19,23-27,29,52-56 * page 175, abstract * DOI: http://dx.doi.org/10.2220/biomedres.33.175 | [X] - HUNTER D, "Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis", OSTEOARTHRITIS AND CARTILAGE 20180401 W.B. SAUNDERS LTD NLD, (20180401), vol. 26, no. Supplement 1, ISSN 1522-9653, XP002793804 [X] 1-11,13,23-27,29,52-56 * abstract * DOI: http://dx.doi.org/10.1016/j.joca.2018.02.067 | by applicant | US4511069 | US4778810 | US6080762 | US7052678 | US8277781 | US9084786 | - M. NAEF et al., "Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans", J. PHARM. SCI., (20040000), vol. 93, doi:doi:10.1002/jps.20037, pages 1176 - 84, XP008140183 DOI: http://dx.doi.org/10.1002/jps.20037 | - CAREYSUNDBERG, Advanced Organic Chemistry, Plenum Press, (19920000), vol. A, B |